MarketPeel
Insider Trading Intelligence
Pricing
…
SH

Samit Hirawat

BMY
EVP,CHIEF MED.OFFR.,DRUG DEV. · BRISTOL MYERS SQUIBB CO · CIK 0001781290
FILING MIX · LIFETIME49%/51%
BUYS
43
SELLS
45
TOTAL VALUE
$5.36M
COMPANIES
2
ACTIVE SINCE
Mar 2020
HOLDINGS NOW
94,404
AVG SELL PX
$63.42
TRADE KIND
SHOWING 88 / 88
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
3 backtested trades · 8 horizons · 3 pending
Forward-return performance of every backtestable P/S trade by Samit Hirawat, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d3+66.67%+2.94%+2.03%+0.91%+2.65%—
14d3+66.67%+3.69%+0.84%+2.85%+0.92%—
30d3+66.67%+6.48%+1.30%+5.18%+4.64%—
60d3+33.33%-1.64%+0.54%-2.18%+1.15%—
90d3+66.67%-1.32%+6.22%-7.54%-12.14%—
180d3+0.00%-8.71%+8.37%-17.08%-17.31%—
1y3+66.67%+6.69%+20.67%-13.98%-7.09%—
2y3(3 pending)——————
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
BMY · 83,513.486 shares · as of Apr 25, 2025
024,76049,52074,28099,04020212022202320242025SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 43 buys / 45 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
10,891——10,891Jun 10, 2026Jun 12, 2026 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
6,405——6,405Jun 10, 2026Jun 12, 2026 ↗View →
PCRX
PACIRA BIOSCIENCES, INC.
PURCHASEGRANT
Stock grant
39,291——39,291Jan 27, 2026Jan 29, 2026 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
4,250$47.58$202.2K83,513.486Apr 25, 2025Apr 29, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
2,327$63.11$146.9K66,154.486Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
5,854——11,711Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,886——0Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
4,765——70,919.486Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
5,854——73,929.486Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
998——72,931.486Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
831——70,088.486Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASEGRANT
Stock grant
35,146——35,146Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
28,593——99,040.486Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,765——4,767Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
28,593——0Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
2,484$63.11$156.8K70,447.486Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
4,886——68,818.486Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
2,013$63.11$127.0K68,075.486Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
10,545——88,495.486Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
9,232$63.11$582.6K79,263.486Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASEGRANT
Stock grant
52,720——52,720Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
337——68,481.486Mar 10, 2025Mar 12, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
1,823.486$54.84$100.0K63,932.486Feb 14, 2025Feb 19, 2025 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
1,830$54.68$100.1K62,109Nov 1, 2024Nov 5, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,885——4,886Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
29,311——80,256Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASEGRANT
Stock grant
60,952——60,952Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
660——50,777Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
10,203——70,053Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
4,885——53,855Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
29,311——0Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,765——9,532Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASEGRANT
Stock grant
40,635——40,635Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
4,192——51,437Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
1,807$53.79$97.2K48,970Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,192——0Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
9,774$53.79$525.7K60,279Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
5,854——17,565Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
842——53,013Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
2,068$53.79$111.2K50,945Mar 10, 2024Mar 12, 2024 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
9,357——52,032Jul 1, 2023Jul 5, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,787$63.95$306.1K47,245Jul 1, 2023Jul 5, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
9,357——0Jul 1, 2023Jul 5, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
2,909$65.71$191.2K26,494Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
4,189——25,481Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASEGRANT
Stock grant
23,419——23,419Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,189——4,192Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
25,139——54,035Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,885——9,771Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASEGRANT
Stock grant
35,129——35,129Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
775——26,256Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,765——14,297Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
4,885——28,601Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
4,765——31,259Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
2,540$65.71$166.9K23,716Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
2,517$65.71$165.4K28,896Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
802——29,403Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
25,139——0Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
154——31,413Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
14,429$65.71$948.1K42,675Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
3,069——57,104Mar 10, 2023Mar 14, 2023 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,786$76.84$367.8K21,292Jul 1, 2022Jul 5, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
9,356——9,357Jul 1, 2022Jul 5, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
9,356——26,078Jul 1, 2022Jul 5, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
2,426$68.42$166.0K14,068Mar 10, 2022Mar 14, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
553——16,494Mar 10, 2022Mar 14, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
4,189——15,941Mar 10, 2022Mar 14, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASEGRANT
Stock grant
19,062——19,062Mar 10, 2022Mar 14, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
548——19,501Mar 10, 2022Mar 14, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,885——14,656Mar 10, 2022Mar 14, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
4,885——18,953Mar 10, 2022Mar 14, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASEGRANT
Stock grant
28,593——28,593Mar 10, 2022Mar 14, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
2,779$68.42$190.1K16,722Mar 10, 2022Mar 14, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,189——8,381Mar 10, 2022Mar 14, 2022 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
9,356——18,713Jul 1, 2021Jul 6, 2021 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,786$66.56$318.6K11,752Jul 1, 2021Jul 6, 2021 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
9,356——16,538Jul 1, 2021Jul 6, 2021 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
1,978$60.93$120.5K7,182Mar 10, 2021Mar 12, 2021 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASEGRANT
Stock grant
19,541——19,541Mar 10, 2021Mar 12, 2021 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASEGRANT
Stock grant
29,311——29,311Mar 10, 2021Mar 12, 2021 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
78——9,160Mar 10, 2021Mar 12, 2021 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
4,189——9,082Mar 10, 2021Mar 12, 2021 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,189——12,570Mar 10, 2021Mar 12, 2021 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
9,356——28,069Jul 1, 2020Jul 2, 2020 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASE
EVP,Chief Med.Offr.,Drug Dev.
9,356——9,356Jul 1, 2020Jul 2, 2020 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
SALE
EVP,Chief Med.Offr.,Drug Dev.
4,463$59.43$265.2K4,893Jul 1, 2020Jul 2, 2020 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASEGRANT
Stock grant
25,139——25,139Mar 10, 2020Mar 12, 2020 ↗View →
BMY
BRISTOL MYERS SQUIBB CO
PURCHASEGRANT
Stock grant
16,759——16,759Mar 10, 2020Mar 12, 2020 ↗View →
Other insiders · BMY
Loading peer insiders…
About this filer
CIK 0001781290
ROLE
EVP,Chief Med.Offr.,Drug Dev.
PRIMARY
BMY
COMPANIES
2
ACTIVE SINCE
Mar 2020
MARKETPEEL · /INSIDER/0001781290DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback